Tianjin Medical University Cancer Institute And Hospital

This early-phase trial is testing whether the experimental drug zeprumetostat, which blocks a protein called EZH2, can work together with either another targeted drug (golidocitinib) or a standard chemotherapy regimen (GemOx) to shrink tumors in people with a rare and aggressive …

This phase II trial tests a personalized approach for people with locally advanced esophageal cancer. After initial chemoimmunotherapy, patients whose tumors shrink well go straight to surgery, while those with less response receive additional radiotherapy before surgery. The goa…

This phase 2 trial tests a new drug called ivonescimab (AK112) combined with chemotherapy (irinotecan and cisplatin) for people with metastatic digestive system neuroendocrine cancer that has spread. Some participants also receive a procedure called TACE, which blocks blood flow …

This phase II trial tests a combination of three drugs—Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib—in people with advanced esophageal squamous cell carcinoma whose cancer has progressed after first-line therapy. The study aims to see if this triple therapy can shrink…

This phase 2 trial tests whether giving a combination of an immunotherapy drug (serplulimab), an epigenetic drug (decitabine), and chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colorectal cancer. The study enrolls 35 adults with previou…

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan (Sac-TMT) and fruquintinib—as a second-line treatment for people with advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after initial therapy. The study enrolls about 45 par…

This study tests whether a personalized nursing program can prevent acute kidney injury (AKI) in people with liver cancer who undergo interventional therapy. Researchers first use a prediction model to classify patients into low, moderate, or high risk for AKI. Then, they provide…

This phase II trial tests a special type of radiation called lattice radiation therapy (LRT) combined with standard chemoimmunotherapy for people with stage III lung cancer that did not shrink enough after initial treatment. The LRT delivers high-dose radiation to specific spots …

This study tests a drug called SHR-A1811 in 60 adults with HER2-positive advanced breast cancer who have had up to 2 prior treatments. Researchers want to see if giving the drug in different ways (like injection or infusion) can shrink tumors. The main goal is to measure how many…

This Phase 2 trial tests whether adding the antihistamine diphenhydramine to the immunotherapy drug toripalimab and standard chemotherapy helps shrink tumors more effectively in people with operable non-small cell lung cancer. About 120 participants will receive either the combin…

This Phase 2 trial tests whether giving two drugs (anlotinib and benmelstobart) before surgery can improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drug combo followed by partial nephrectomy, or surgery alone. The main goal …

This study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…

This phase 2 trial tests a combination of two targeted drugs (donafenib and sintilimab) plus chemotherapy delivered directly to the liver as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study will enroll 90 participants and measur…

This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to elderly patients (70+) with HER2-positive breast cancer. The goal is to see if this approach can completely eliminate cancer cells in t…

This study tests a drug called adebrelimab combined with chemotherapy before deciding on surgery for people with a certain type of esophageal cancer. About 200 participants will receive the treatment first. If the cancer disappears completely on scans, they will be randomly assig…

This study tests whether giving chemotherapy directly into the liver along with standard chemo pills and IV drugs can help prevent colorectal cancer from coming back after surgery to remove tumors from the liver. About 28 adults who have had successful surgery and show no remaini…

This phase 2 trial tests whether adding an experimental immunotherapy (iparomlimab and tuvonralimab) to targeted radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 people with stage I-IIB disease will receive the drug every 3 weeks for a year, star…

This phase 2 trial tests whether adding the experimental drug rilapentib alpha to standard chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer that does not have certain gene mutations. Participants will receive the drug combination before su…

This study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard im…

This phase II trial tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can reduce the risk of liver cancer returning in patients with early-stage disease and narrow surgical margins. Sixty participants will be randomly assigned to receive the drug combina…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults with early-stage liver cancer (stage IB or IIA) will receive…

This phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study ai…

This early-stage trial is testing a new treatment called CHT101 for adults with aggressive brain tumors that have returned or worsened despite standard care. CHT101 is a type of immune cell therapy (CAR T-cells) designed to recognize and attack tumor cells carrying a protein call…

This phase 2 trial tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery in 26 patients with locally advanced esophageal cancer. The goal is to see if this approach can completely eliminate cancer cells in the removed tis…

This phase II trial tests whether combining two drugs—sacituzumab tirumotecan and toripalimab—given before surgery can shrink tumors in people with stage II to IIIB non-small cell lung cancer (NSCLC). About 38 participants will receive the drugs intravenously over several weeks, …

This study tests whether adding the immunotherapy drug camrelizumab to chemotherapy and radiation before surgery can eliminate all signs of early-stage triple-negative breast cancer. About 43 women with newly diagnosed, untreated disease will receive the combination for 12 weeks,…

This early-phase trial tests whether adding an experimental immunotherapy drug (Retlirafusp alfa) to standard chemotherapy can improve outcomes for people with gastroesophageal junction adenocarcinoma. About 30 patients will receive the drug combination before surgery, and some m…

This study will follow 500 people with HER2-positive advanced breast cancer who are starting treatment with pyrotinib, a daily oral targeted therapy. Researchers want to see how well the drug controls the cancer and what side effects occur in everyday medical practice, not just i…

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This phase 2 trial tests a combination of two drugs—entinostat and oral paclitaxel—in 50 people with HR-positive, HER2-negative advanced breast cancer who have already tried 2 to 4 prior treatments. The goal is to see if the combo can delay cancer growth. Participants take both d…

This study tests a combination of chemotherapy drugs (liposomal irinotecan, vincristine, and temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have returned or not responded to treatment. The goal is to see if this combination c…

This study tests a combination of chemotherapy delivered directly to the liver, an oral targeted drug, and an immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors. The trial will enroll 30…

This study is for people with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. Researchers are testing whether adding an immunotherapy drug (toripalimab) and targeted radiation before and after surgery can improve outcomes. About 110 participant…

This phase II trial tests a combination of three drugs (adebrelimab, nimotuzumab, and chemotherapy) given before surgery to 22 patients with resectable esophageal squamous cell carcinoma. The main goal is to see if the cancer disappears completely after treatment. If it works, th…

This Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possib…

This study tests whether a higher dose of furmonertinib alone works better than a standard dose combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutated) that has spread to the brain. About 60 adults who have not had prior treatment will be enrolled…

This phase 2 trial tests iruplinalkib tablets as a daily treatment after surgery for people with stage IA ALK-positive non-small cell lung cancer who have high-risk factors. The goal is to see if the drug can prevent the cancer from coming back. About 28 participants will take th…

This phase 2 study is testing fluzoparib, a daily pill, as a maintenance therapy for people with advanced triple-negative breast cancer whose disease was controlled by platinum chemotherapy. The trial will enroll 72 participants with or without BRCA gene mutations. The goal is to…

This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…

This study tests a combination of four drugs—tunlametinib, two chemotherapies, and a targeted antibody—as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The trial will enroll 28 patients who have not had prior therapy. Researchers …

This study is for people with esophageal cancer that did not shrink after initial treatment. It tests whether adding low-dose radiation to a combination of immunotherapy (toripalimab) and chemotherapy can improve outcomes. Participants will receive the treatment before surgery, a…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib or axitinib) in 36 adults with advanced clear cell kidney cancer that has worsened after initial treatment. The main goal is to see if the combination can …

This phase 2 trial tests whether a mix of immunotherapy (iparomlimab and tuvonralimab), chemotherapy (gemcitabine and oxaliplatin), and a targeted drug (lenvatinib) can shrink bile duct and gallbladder cancers enough to be surgically removed. About 29 adults with locally advanced…

This phase 2 trial tests whether adding an experimental immunotherapy (QL1706) to standard chemotherapy and targeted drugs can better eliminate HER2-positive breast cancer before surgery. About 188 people with early or locally advanced disease will be randomly assigned to receive…

This Phase 3 trial tests whether the immunotherapy drug toripalimab can help prevent cancer from growing in people with advanced esophageal cancer who have already received chemotherapy and radiation. About 340 participants will be randomly assigned to receive toripalimab or just…

This phase 2 trial tests a combination of two drugs—Sacituzumab Tirumotecan and Toripalimab—as a first treatment for people with a specific type of advanced triple-negative breast cancer that is PD-L1 positive. The study aims to see if the combo shrinks tumors and improves surviv…

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and bevacizumab—in 31 adults with advanced non-squamous lung cancer that has worsened after initial treatment. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive t…

This study tests a new treatment for mantle cell lymphoma, a rare blood cancer. It combines chemotherapy with targeted drugs to see if it can keep the cancer from coming back. The study involves 45 people who have not been treated before, and uses scans and blood tests to guide t…

This phase 2 trial is testing several drug combinations as a first treatment for extensive-stage small cell lung cancer. Researchers will assign 165 participants to different treatment arms based on specific biomarkers in their tumors. The goal is to see if matching therapy to th…

This study tests a drug called romiplostim N01 in 68 breast cancer patients whose platelet counts dropped too low due to chemotherapy. The goal is to see if weekly injections can bring platelet levels back up within two weeks, so patients can safely continue their cancer treatmen…

This Phase 2 trial is testing a combination of two drugs—Sacituzumab tirumotecan and Tagitanlimab—in people with a specific type of advanced breast cancer called PD-L1-positive triple negative breast cancer. The study will enroll 47 participants whose cancer has already been trea…

This phase 2 trial is testing a combination of three drugs—gecacitinib, donafenib, and a PD-1 inhibitor—as a second-line treatment for people with advanced liver cancer that did not respond to initial immunotherapy. The study will enroll 35 participants and measure how well the t…

This phase II trial investigates whether a specially formulated yogurt rich in butyrate—a short-chain fatty acid—can relieve constipation in people with gastrointestinal cancer. Constipation is a common and distressing side effect of cancer and its treatments, and current medicat…

This study tests a new painkiller called anrikefon in 114 people recovering from laparoscopic stomach cancer surgery. The drug aims to control pain with fewer side effects like nausea and drowsiness than standard opioids. Researchers will measure how much extra opioid pain medici…

This study tests whether a combination of two anti-nausea drugs (NEPA plus megestrol acetate) works better than the standard regimen (NEPA plus dexamethasone) for preventing nausea and vomiting in breast cancer patients receiving T-DXd therapy. 120 participants will be randomly a…

This study looks at whether a blood test can predict how well the drug deruxtepruzumab works in people with advanced breast cancer that has low or ultra-low levels of a protein called HER2. Researchers will track cancer cells and HER2 levels in the blood of 100 patients during tr…

This study looks at 860 Chinese patients with advanced kidney cancer to see which order of treatments works better: starting with one drug combo and switching to another, or the reverse. The goal is to find the best sequence to help patients live longer and feel better. Participa…

This study looks at 300 lung cancer patients who had immunotherapy before surgery but still had cancer cells left after the operation. Researchers will use advanced gene testing to find hidden genetic changes that might explain why the cancer didn't fully disappear. The goal is t…